KR920014467A - 경구용 글리코스아미노글리칸을 함유하는 제약학적 조성물 - Google Patents

경구용 글리코스아미노글리칸을 함유하는 제약학적 조성물 Download PDF

Info

Publication number
KR920014467A
KR920014467A KR1019920001330A KR920001330A KR920014467A KR 920014467 A KR920014467 A KR 920014467A KR 1019920001330 A KR1019920001330 A KR 1019920001330A KR 920001330 A KR920001330 A KR 920001330A KR 920014467 A KR920014467 A KR 920014467A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
weight
surfactant
coating
sodium
Prior art date
Application number
KR1019920001330A
Other languages
English (en)
Other versions
KR100210359B1 (ko
Inventor
크리스토포리 만리오
마치 에지디오
Original Assignee
귀도 게라
알파 와셔만 에스.피.에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 귀도 게라, 알파 와셔만 에스.피.에이 filed Critical 귀도 게라
Publication of KR920014467A publication Critical patent/KR920014467A/ko
Application granted granted Critical
Publication of KR100210359B1 publication Critical patent/KR100210359B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

경구용 글리코스아미노글리칸을 함유하는 제약학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 사람의 섬유소판 플라스미노겐의 활성화체를 주로 함유한 유글로불린(euglobulin) 프랙션의 용해의 값을 도시한 도표, 제2도는 농도로서 플라스미노겐의 활성화체의 억제제를 도시한 도표, 제3도는 기능 테스트에 의한 플라스미노겐의 활성화체의 억제제를 도시한 도표.

Claims (6)

  1. 장(腸)에서 용해가능한 위(胃)내성 막으로 코팅된 경구용 제약학적 조성물로서, 이 조성물은 농후화물질 및 표면활성제와 함께 치료에 효과적인 량의 글리코스 아미노글리칸으로 이루어진 라이어필리세이트(lyophilisate)를 포함하는 것을 특징으로 하는 경구용 제약학적 조성물.
  2. 제1항에 있어서, 태블렛, 캡슐 및 슈가 코팅된 태블렛으로 부터 선택되는 것을 특징으로 하는 제약학적 조성물.
  3. 제1항 또는 2항중 어느 한항에 있어서, 조성물은 헤파린 및 그 알카리염 또는 알칼리 토류염, 저분자량 헤파린의 프랙션(fraction), 데르마탄설페이트 및 그 저분자량 프랙션 및 술로덱사이드(INN)로서 공지된 글루쿠로닐글리코스 아미노글리칸을 25-250mg 함유하며, 장에서 용해 가능한 위 내성막은 셀룰로오즈 아세테이트 유도라기트(Eudragit)로서 공지된 메쓰아크릴산과 메쓰아크릴산 에스텔의 서로다른 비율의 공중합체, 폴리비닐 아세토 프탈레이트 및 히드록시프로필 메틸셀룰로오즈 프탈레이트로 부터 선택된 코팅물질과 디에틸프탈레이트, 트리아세틴, 폴리에텔렌글리콜 및 아세틸화 모노글리세리드로 부터 선택된 가소제로 이루어지고 그 중량은 코팅되지않은 제약학적 조성물의 2-10중량% 이며, 농후화 물질은 아라비아검, 트래거캔스 검, 크산탄 검, 펙틴 전분, 카라게닌, 알기네이트, 카제인, 젤라틴, 히드록시에틸셀룰로오즈, 메틸셀룰로오즈, 히드록시프로필셀룰로오즈, 카르복시메틸셀룰로오즈, 폴리비닐피롤리돈, 폴리비닐 알코올, 카보풀, 수소화 캐스터 오일, 알루미늄 옥사이드 모노스테레아레이트로 부터 선택되며, 표면활성제는 담즙산(bile acid)의 알칼리염, 유기 카르복실산 알칼리염 및 황산 알칼리염, 알킬 및 아릴 설페이트의 알칼리염, 천연원의 포스포리피드, 지방산과 모노- 및 디-삭카라이드의 에스테르, 폴리옥시에틸렌 알코올, 및 폴리옥시에틸렌 알코올과 지방산의 에스테르로 부터 선택되는 것을 특징으로 하는 제약학적 조성물.
  4. 제3항에 있어서, 표면활성제는 콜산나트륨(sodium cholate), 글리코콜산 나트륨, 타우로콜산 나트륨, 라우릴살코신산 나트륨, 에그 레시틴, 소야(soja), 레시틴, 삭카로오즈 모노팔미테이트 및 트윈(Tween)으로서 공정된 폴리소르베이트로 부터 선택되는 것을 특징으로 하는 제약학적 조성물.
  5. 제1 내지 3항중 어느 한항에 따른 제약학적 조성물을 제조하는 방법으로서, a)농후화 물질을 증류수에 가열 및 교반시켜 용해시키고 난후 표면활성제를 용해시키고 이 결과의 용액을 냉각시킨 다음, 글리코스아미노글리칸을 포함하는 수용액을 첨가하고 이 결과외 용액을 동결-건조시키는 공정과; b)상기 라이어필리세이트를 함유하며 공지 방법에 따라 제조된 경구용 제약학적 형태에, 95%에틸 알코올과 물 22:1 혼합물에 현탁되어있는 히드록시 프로필메틸 셀룰로오즈, 폴리에틸렌 글리콜 6000, 티타늄 디옥사이드 및 활석의 현탁액을 코팅되지 않은 제약학적 형태의 1-5중량%의 량으로, 코팅팬(coating pan)안에서, 분무함으로써 코딩시키고, 연속적으로 이 제약학적 형태에, 에틸알코올과 물 80:1 혼합물에 들어있는 1종이상의 코팅물질, 1종이상의 가소제 용액을 코팅 되지않는 제약학적 형태의 2-10중량%의 량으로, 코팅팬 안에서 분무함으로써, 장에서 용해가능한 위 내성막을 코팅시키는 공정을 포함하는 것을 특징으로 하는 제약학적 조성물의 제조방법.
  6. 제1 내지 3항에 따른 제약학적 조성물을 혈전증 및 동맥경화증의 예방 및 치료에 사용하는, 제약학적 조성물의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920001330A 1991-01-30 1992-01-30 경구용 글리코스아미노글리칸을 함유하는 의약 조성물 KR100210359B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITBO91A000024 1991-01-30
ITBO910024A IT1245761B (it) 1991-01-30 1991-01-30 Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.

Publications (2)

Publication Number Publication Date
KR920014467A true KR920014467A (ko) 1992-08-25
KR100210359B1 KR100210359B1 (ko) 1999-07-15

Family

ID=11337212

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920001330A KR100210359B1 (ko) 1991-01-30 1992-01-30 경구용 글리코스아미노글리칸을 함유하는 의약 조성물

Country Status (8)

Country Link
US (1) US5252339A (ko)
EP (1) EP0497162B1 (ko)
JP (1) JPH0755907B2 (ko)
KR (1) KR100210359B1 (ko)
CA (1) CA2059865C (ko)
DE (1) DE69212608T2 (ko)
ES (1) ES2090368T3 (ko)
IT (1) IT1245761B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100487083B1 (ko) * 2001-05-09 2005-05-03 주식회사 메디프렉스 양친성 헤파린 유도체의 점막 흡수를 증가시키기 위한제조방법

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1256236B (it) * 1992-12-23 1995-11-29 Mediolanum Farmaceutici Srl Oligosaccaridi aventi attivita' biologica e procedimento per la loro preparazione di glicosaminoglicani
IT1270846B (it) * 1993-05-10 1997-05-13 Alfa Wassermann Spa Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica.
HU219339B (en) * 1993-09-30 2001-03-28 Seikagaku Kogyo Co Ltd Dermatan sulphate with low heparin or heparane sulphate content and pharmaceutical compositions comprising them
US5888984A (en) * 1994-05-12 1999-03-30 Dermal Research Laboratories, Inc. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
DE19501266A1 (de) * 1995-01-18 1996-07-25 Madaus Ag Verfahren zur Herstellung von Flavano-Lignan-Zubereitungen mit verbesserter Freisetzung und Resorbierbarkeit danach erhältliche Zubereitungen und deren Verwendung zur Herstellung von Arzneimitteln
US6262255B1 (en) 1995-04-05 2001-07-17 Biomm, Inc. Non-immunogenic, biocompatible macromolecular membrane compositions, and methods for making them
GB2305604B (en) * 1995-09-29 1999-06-23 Quest Vitamins Ltd Carrier base material
CA2235223A1 (en) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase i
IT1285546B1 (it) * 1996-01-16 1998-06-18 Alfa Wassermann Spa Uso del dermatano solfato a basso peso molecolare e delle specialita' medicinali che lo contengono nella terapia e nella prevenzione della
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US7691829B2 (en) * 1998-03-24 2010-04-06 Petito George D Composition and method for healing tissues
US6476005B1 (en) 1998-03-24 2002-11-05 George D. Petito Oral and injectable nutritional composition
US6645948B2 (en) 1998-03-24 2003-11-11 George D. Petito Nutritional composition for the treatment of connective tissue
US20050208114A1 (en) * 1998-03-24 2005-09-22 Petito George D Composition and method for healing tissues
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
JP2003527822A (ja) * 1998-08-27 2003-09-24 マサチューセッツ インスティテュート オブ テクノロジー ヘパリナーゼｉおよびｉｉ由来の合理的に設計されたヘパリナーゼ
IL127826A0 (en) * 1998-12-29 1999-10-28 Laster Gail Restenosis drug therapy
IL127896A0 (en) * 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
AU2745700A (en) 1999-02-01 2000-08-18 Dermal Research Laboratories, Inc. A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
EP1154761B1 (en) * 1999-02-22 2008-02-20 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
WO2000065521A2 (en) 1999-04-23 2000-11-02 Massachusetts Institute Of Technology System and method for polymer notation
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
MXPA02000142A (es) * 1999-06-30 2003-07-21 Hamilton Civic Hospitals Res Composiciones de heparina que inhiben los factores de coagulacion asociados con el coagulo.
WO2001066772A2 (en) * 2000-03-08 2001-09-13 Massachusetts Institute Of Technology Heparinase iii and uses thereof
US7259152B2 (en) * 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
JP2004507562A (ja) * 2000-09-08 2004-03-11 ハミルトン　シビック　ホスピタルズ　リサーチ　ディベロップメント　インコーポレイテッド 抗血栓性組成物
CA2422059C (en) 2000-09-12 2012-05-15 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
CA2423469A1 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
WO2002064148A2 (en) * 2001-02-16 2002-08-22 Shimizu Pharmaceutical Co., Ltd. Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
EP1372611B1 (en) * 2001-03-26 2006-05-17 Novartis AG Pharmaceutical composition comprising a poorly water-soluble staurosporine, a surfactant and a water-soluble polymer
BRPI0101486B1 (pt) * 2001-04-17 2017-09-19 Cristália Produtos Químicos Farmacêuticos Ltda. Pharmaceutical composition for topic use containing heparin for the treatment of skin or mucosal injuries caused by burns
JP4489356B2 (ja) 2001-05-11 2010-06-23 メリオン リサーチ スリー リミテッド 浸透促進剤
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US20030013680A1 (en) * 2001-06-12 2003-01-16 Keryx Methods using glycosaminoglycans for the treatment of nephropathy
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US20030228368A1 (en) * 2001-09-28 2003-12-11 David Wynn Edible solid composition and dosage form
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
WO2004112756A1 (en) 2003-06-26 2004-12-29 Isa Odidi Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US20060004098A1 (en) * 2003-07-28 2006-01-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds useful for treating neurological disorders
US20050181047A1 (en) * 2004-02-18 2005-08-18 Jaime Romero Compositions and methods for timed release of water-soluble nutritional supplements
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060229276A1 (en) * 2004-07-28 2006-10-12 Magnus Hook Use of glycosoaminoglycans for the prevention and treatment of sepsis
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
JP2006298791A (ja) * 2005-04-18 2006-11-02 Kotobuki Seiyaku Kk グリコサミノグリカン又はその塩を含む経口投与用医薬品、健康食品又は栄養薬品組成物。
US8298602B2 (en) * 2005-10-11 2012-10-30 Purecircle Sdn Bhd Process for manufacturing a sweetener and use thereof
AU2006322076C1 (en) 2005-12-08 2013-11-14 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US9561188B2 (en) 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
EP2012750B1 (en) * 2006-04-06 2018-02-21 Insmed Incorporated Methods for coacervation induced liposomal encapsulation and formulations thereof
MX2008012678A (es) 2006-04-07 2008-12-17 Merrion Res Iii Ltd Forma de dosis oral solida que contiene un mejorador.
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
KR20110007242A (ko) 2008-05-07 2011-01-21 메리온 리서치 Ⅲ 리미티드 펩티드 조성물 및 그의 제조 방법
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2011086194A1 (en) * 2010-01-18 2011-07-21 Cephalon France Improved oral lysophilisates containing pvp/va
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CN103476419A (zh) 2011-01-07 2013-12-25 梅里翁第三研究有限公司 口服投药的含铁药物组合物
EP2834635A4 (en) * 2012-04-03 2015-09-02 Smiths Medical Asd Inc COMPOSITIONS WITH A HEPARINE ACCUMULATIVE AND METHOD THEREFOR
KR102092361B1 (ko) 2012-05-21 2020-03-23 인스메드 인코포레이티드 폐 감염을 치료하기 위한 시스템
MX2015006681A (es) 2012-11-29 2016-04-06 Insmed Inc Formulaciones de vancomicina estabilizadas.
ES2981634T3 (es) 2014-05-15 2024-10-09 Insmed Incorporated Métodos para tratar infecciones micobacterianas pulmonares no tuberculosas
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
ES2975708T3 (es) 2015-01-29 2024-07-12 Novo Nordisk As Comprimidos que comprenden agonista del GLP-1 y recubrimiento entérico
JP2020503269A (ja) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド 経口ウンデカン酸テストステロン療法
EP3773505A4 (en) 2018-03-30 2021-12-22 Insmed Incorporated PROCESS FOR THE CONTINUOUS MANUFACTURING OF LIPOSOMAL MEDICINAL PRODUCTS

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3548052A (en) * 1964-10-27 1970-12-15 Canada Packers Ltd Heparin compositions and methods of using same
US3482014A (en) * 1966-06-29 1969-12-02 Canada Packers Ltd Orally active heparin and method for making and using same
US3506642A (en) * 1967-07-03 1970-04-14 Canada Packers Ltd Stable orally active heparinoid complexes
US3574832A (en) * 1968-05-29 1971-04-13 American Cyanamid Co Therapeutic heparin-surfactant compositions
US3577534A (en) * 1968-06-20 1971-05-04 Canada Packers Ltd Stable orally active heparinoid complexes
IT1062779B (it) * 1974-04-04 1985-01-14 Crinos Industria Farmaco Composizione farmaceutica contenente un fattore eparinoidico
IT1069492B (it) * 1976-10-13 1985-03-25 Alfa Farmaceutici Spa Composizione farmaceutica sommini stratrice per via orale contenente un fattore eparinoide sospeso in un veicolo oleoso costituito da triace tato di glicerina
GB1591306A (en) * 1976-10-23 1981-06-17 Choay Sa Liposomes containing heparin and a process for obtaining them
FR2492259A1 (fr) * 1980-10-21 1982-04-23 Idinvex Sa Formulation d'heparine
US4654327A (en) * 1982-04-21 1987-03-31 Research Corp. Quaternary ammonium complexes of heparin
US4604376A (en) * 1982-04-21 1986-08-05 Research Corporation Enteric compounds and complexes
US4510135A (en) * 1982-04-21 1985-04-09 Research Corporation Orally administered heparin
CH656533A5 (de) * 1982-12-10 1986-07-15 Sandoz Ag Therapeutisches praeparat enthaltend hydrierte ergotalkaloide und niedermolekulares heparin.
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
JPS6054313A (ja) * 1983-09-01 1985-03-28 Terumo Corp 腸管吸収性ヘパリン組成物
EP0189427B1 (en) * 1984-05-21 1989-02-08 BODOR, Nicholas S. Orally active heparin multiplets
US5102788A (en) * 1988-11-21 1992-04-07 Hygeia Sciences, Inc. Immunoassay including lyophilized reactant mixture
US5032405A (en) * 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100487083B1 (ko) * 2001-05-09 2005-05-03 주식회사 메디프렉스 양친성 헤파린 유도체의 점막 흡수를 증가시키기 위한제조방법

Also Published As

Publication number Publication date
ITBO910024A0 (it) 1991-01-30
ITBO910024A1 (it) 1992-07-30
JPH0755907B2 (ja) 1995-06-14
DE69212608T2 (de) 1996-11-28
JPH0543471A (ja) 1993-02-23
CA2059865C (en) 1999-01-26
EP0497162B1 (en) 1996-08-07
ES2090368T3 (es) 1996-10-16
DE69212608D1 (de) 1996-09-12
IT1245761B (it) 1994-10-14
US5252339A (en) 1993-10-12
EP0497162A1 (en) 1992-08-05
KR100210359B1 (ko) 1999-07-15
CA2059865A1 (en) 1992-07-31

Similar Documents

Publication Publication Date Title
KR920014467A (ko) 경구용 글리코스아미노글리칸을 함유하는 제약학적 조성물
Pearnchob et al. Improvement in the disintegration of shellac-coated soft gelatin capsules in simulated intestinal fluid
KR102177773B1 (ko) 지연 방출형 약물 제형
JP2773959B2 (ja) 大腸内放出性固形製剤
ES2657673T3 (es) Formulaciones recubiertas entéricas de pancrelipasa, de baja intensidad
BG104634A (bg) Микрогранули от омепразол със стомашно защитно действие, метод за тяхното получаване и фармацевтични препарати
PT89276B (pt) Processo para a preparacao de uma formulacao farmaceutica de libertacao prolongada constituida por microgranulos revestidos com etilcelulose e eudragit rs (resina acrilica, polimerizado de esteres dos acidos acrilico e metacrilico)
JP6273356B2 (ja) 遅延放出性薬物製剤
KR920019358A (ko) 담즙산 염을 함유하는 경구용 위 내성 의약 포뮬레이션
EP0453001A1 (en) Pharmaceutical composition for the targeted controlled release of an active principle within the intestine, and particularly within the colon
JP2007530683A (ja) 経口摂取可能な基材の腸溶性コーティング
KR920019360A (ko) 담즙산과 그 염을 함유하는 경구용 제어 방출 위 내성 의약 포뮬레이션
WO2013145379A1 (ja) 大腸特異崩壊性カプセル
PT93028A (pt) Processo para a preparacao de uma composicao contendo acido 5-(2,5-dimetil- fenoxi)-2,2-dimetil-pentanoico (gemfibrozilo) de libertacao prolongada
JPWO2017022248A1 (ja) 腸溶性カプセル
JPS61145124A (ja) 膵臓酵素製品およびその製造方法
KR890001535A (ko) 요독증의 치료에 유용한 약학 조성물
JP6626470B2 (ja) 遅延放出性薬物製剤
SE462779B (sv) Farmaceutisk komposition innehaallande n-acetylcystein i en kaerna belagd med hydroxipropylmetylcellulosaftalat
JPH0725663B2 (ja) 腸溶性軟カプセルの製造方法
US20160309772A1 (en) Enteric coating composition, enteric coating film, and food formulation
JP3122478B2 (ja) 下部消化管放出型経口製剤
JPH089536B2 (ja) 腸溶性カプセルの製造方法
JPH0669476B2 (ja) ゼラチン硬カプセルのフイルムコ−テイング方法
KR20210100664A (ko) 결장 약물 운반 제형

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110412

Year of fee payment: 13

EXPY Expiration of term